Evidence map›Paper›PMID 40206091›Full record

ArticleFrontiers in pharmacology2025

Zhifeng Yang, Yuqian Chang, Tong Zhou, Wenwen Sui, Ping Dai, Yuan Wei, Jia-Sheng Wang, Jun Zhou, Chengli Wen, Haidong Zhang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Combatting pulmonary fibrosis withChinese herbal medicines · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhifeng Yang *Shandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yuqian Chang *Shandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Tong ZhouAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Wenwen SuiPeople's Hospital of Dongying District, Dongying, Shandong, China.
Ping DaiShandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yuan WeiShandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jia-Sheng WangShandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jun ZhouShandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Chengli WenShandong Center for Disease Control and Prevention, Jinan, Shandong, China.
Haidong ZhangShandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: Here, we evaluate the mitigating function of DBT on lung inflammation and early fibrosis in a rat model. The model was established by tracheal dripping of silica suspension for 28 days. Positive intervention effects of DBT were observed in a dose-dependent manner after consecutive gavage of DBT (1.9, 3.8, and 7.6 g/kg·bw/d) for 28 days and 42 days. To explore the underlying molecular mechanism. DBT metabolites were profiled using a liquid chromatograph-mass spectrometer and the Chemspider database. Results: Lung inflammation and fibrosis were confirmed using functional tests and histopathologic analysis. Metabolite target analysis identified nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) as a key target of DBT in regulating pulmonary fibrosis. Gene ontology (GO) analysis estimated that oxidative stress, inflammatory response, myofibroblast differentiation, and extracellular matrix (ECM) deposition were the major target pathways of DBT. KEGG analysis found that DBT might modulate pulmonary fibrosis through the transforming growth factor-β (TGF-β) pathway. GO chord and signaling pathway maps revealed that NOX4 contributes to oxidative stress, inflammatory response, and TGF-β pathway regulation. The Discussion: These findings demonstrate the lung-protecting function of DBT in a rat model and identify critical target proteins associated with the underlying mechanism.

Indexed as

botanical drug decoctionDanggui Buxue Tanglung inflammaitonNOX4pulmonary fibrosis

Identifiers

PMID40206091
PMCPMC11978833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.